Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
University of Galway researchers identified that targeting GABA signaling, specifically α5-GABA A receptors, can restore neural balance and improve memory in Alzheimer's disease models, offering a potential new therapeutic approach distinct from current excitatory-focused treatments.
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
A Delphi consensus of 23 experts identified Zostavax, sildenafil and riluzole as high-priority candidates for Alzheimer disease clinical trials. Caregivers ranked the herpes zoster vaccine highest for acceptability and perceived benefit–risk balance.
Deep learning studies using MRI, genetics and longitudinal imaging reported improved dementia risk prediction and mapped dynamic brain-region changes during Alzheimer’s disease progression.
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
New research identifies a key microglial subpopulation regulated by anti-TREM2 antibody therapy in Alzheimer's disease, revealing how the treatment guides microglia toward protective differentiation pathways.
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07693738 |
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE1 |
| NCT07672977 |
Home-Based Closed-Loop Auditory Stimulation to Enhance Slow-Wave Activity in MCI Due to Alzheimer's Disease: A Proof-of-Concept Study |
ENROLLING_BY_INVITATION | NA |
| NCT07252440 |
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease |
RECRUITING | PHASE2 |
| NCT07100470 |
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET |
NOT_YET_RECRUITING | NA |
| NCT07011706 |
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06593626 |
A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection |
COMPLETED | PHASE1 |
| NCT06335836 |
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD) |
RECRUITING | |
| NCT06245031 |
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) |
ENROLLING_BY_INVITATION | NA |
| NCT06155201 |
Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders |
RECRUITING | NA |
| NCT05984784 |
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) |
TERMINATED | PHASE1/PHASE2 |
